Active substance
Desflurane
- SFDA 2
- US FDA 3
- Health Canada 1
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| SUPRANE LIQUID FOR INHALATION | 100 % | Inhalation vapour, liquid · Inhalation use | 6 Bottle | SAR 2148.90 | NCE · Prescription | BAXTER HEALTHCARE CORPORATION | Valid |
| SUPRANE LIQUID FOR INHALATION | 100 % | Inhalation vapour, liquid · Inhalation use | 1 Box | SAR 284.70 | NCE · Prescription | BAXTER HEALTHCARE CORPORATION | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ANESTHESIA
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| SUPRANE | 100% | liquid · inhalation | BAXTER HLTHCARE | Prescription | 18 Sep 1992 |
| DESFLURANE | 100% | liquid · inhalation | PIRAMAL CRITICAL | Prescription | 5 Oct 2026 |
| DESFLURANE | 100% | liquid · inhalation | SHANGHAI HENGRUI | Discontinued | 26 Feb 2018 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| SUPRANE | 02227428 | 100 % / V/V | LIQUID · INHALATION | BAXTER CORPORATION |
Safety signals and safety-related labeling changes
- US FDA 1 Nov 2022 SUPRANE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.